Showing results (141-150 of 333) with videos related to

Sort By:
Pageof 34
Oncotarget|May 26, 2018
A case of <i>ALK</i>-rearranged non-small cell lung cancer that responded to ceritinib after development of resistance to alectinibYosuke Makuuchi, Hidetoshi Hayashi, Koji Haratani, et al.
JTO Clinical and Research Reports|April 3, 2023
First-Line Lorlatinib Versus Crizotinib in <i>ALK</i>-Positive NSCLC: Japanese Subgroup Analysis of CROWNHidetoshi Hayashi, Shunsuke Teraoka, Yasushi Goto, et al.
Cancer Medicine|February 1, 2019
Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancerSatomi Watanabe, Kimio Yonesaka, Junko Tanizaki, et al.
JTO Clinical and Research Reports|March 4, 2024
Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With <i>ALK-</i>Positive Advanced NSCLC-A Brief Report From the CROWN StudyShunsuke Teraoka, Hidetoshi Hayashi, Yasushi Goto, et al.
NPJ Precision Oncology|November 17, 2024
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancerTakaaki Fujimura, Koh Furugaki, Hayato Mizuta, et al.
British Journal of Cancer|December 10, 2020
Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblastsRyoji Kato, Koji Haratani, Hidetoshi Hayashi, et al.
JAMA Oncology|October 5, 2017
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung CancerKoji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, et al.
Pediatric Research|June 2, 2026
Combination of CHK1 and CHK2 inhibitors exerts synergistic antitumor effects against neuroblastoma cellsRina Kato, Hiromasa Aoki, Kohki Toriuchi, et al.
International Journal of Molecular Sciences|February 11, 2023
Monocyte-Derived miRNA-1914-5p Attenuates IL-1β-Induced Monocyte Adhesion and TransmigrationKohki Toriuchi, Toshie Kihara, Hiromasa Aoki, et al.
Biochemical and Biophysical Research Communications|March 21, 2024
ID3 is a novel target gene of p53 and modulates lung cancer cell metastasisMai Nagasaka, Chiharu Miyajima, Yasumichi Inoue, et al.
Pageof 34